N/A
N=38
Clinical Study to Evaluate the Efficacy of an Over-the-counter (OTC) Sunscreen Lip Balm Product
Sunscreening Agents
Bottom Line
View on ClinicalTrials.gov: NCT05109117 ↗Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Mar 2024
Primary outcome: Primary: Mean Change From Baseline in Corneometer Measurements — 23.5; 24.2; 2.4; -0.6 Arbitrary units — p=<0.0001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- CAP Unscented (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- HALEON
- Primary completion
- Dec 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Change From Baseline in Corneometer Measurements |
23.5; 24.2; 2.4; -0.6; 1.7; -0.1 | <0.0001 sig |
| SECONDARY Percentage of Participants With Improved Corneometer Measurement |
69.4; 38.9; 66.7; 44.4; 66.7; 55.6 | — |
Summary
The purpose of this study is to evaluate the 8-hour moisturization efficacy of OTC sunscreen lip balm after a single treatment application.
Eligibility Criteria
Inclusion Criteria
- Participant must provide a signed and dated, legally effective, informed consent document, which indicates they have been informed of, and understand, all pertinent aspects of the study, before any study procedures are performed (in conformance with 21 Code of Federal Regulations [CFR] Part 50: 'Protection of Human Subjects.')
- Participant must provide relevant details of their medical history and current/recent medications and treatments.
- Participant has completed a Health Insurance Portability and Accountability Act (HIPAA) Authorization Form in conformance with 45 CFR Parts 160 and 164.
- Participant must have completed a Photo Release Form.
- Participant must be able to read, write, speak and understand English.
- Participant must be in good general health.
- Participant must have a valid form of personal identification (photo identity [ID], driver's license, passport, permanent resident card, military ID card; forms cannot be expired)
- Male and female participants of child-bearing potential must agree to use a highly effective method of contraception for the duration of the study and for 14 days after treatment application. (Note: A participant is considered to be of child-bearing potential if, in the opinion of the Principle investigator [PI], they are biologically capable of having children and sexually active.
- Participant must agree to be sequestered in a temperature/humidity monitored test room at the clinical site (temperature 21 degree Celsius [C] +/- 2 degree C, relative humidity [RH] 50 percent [%] +/- 10%) for the duration of the test day (Visit 2), approximately 9.5 hours.
- Participant must agree to bring their own food (dry) and beverages to be consumed on the test day (Visit 2).
- Participant must agree not to consume hot or very cold food/beverages on the test day (Visit 2).
- Participant must agree to use the non-moisturizing soap provided for all personal washing during the conditioning phase of the study.
- Participant must agree to wear loose clothing for ease of access to the test sites (arms) and/or sleeves that can be easily rolled up.
- Participant must agree not to introduce any new cosmetic/toiletry products into their personal care regimen during the study.
- Participant must agree to refrain from any physical effort which might result in thermal regulation by sweating (for example, exercise class, rapid climbing of flights of stairs, jogging, cycling, brisk walking) for at least 2 hours prior to arriving the test day (Visit 2).
- Participant must agree to refrain from prolonged or excessive ultraviolet (UV) exposure (for example, sunbathing, tanning beds) for the duration of the study.
- Participant should be dependable and able to follow directions as outlined in the protocol and Informed Consent Form (ICF).
Exclusion Criteria
- Participant with scheduled or planned Covid-19 vaccination during likely dates of study participation.
- Female participant who is pregnant, planning to become pregnant during the study, or breastfeeding ( self-reported).
- Participant with a history of sensitivity to any ingredient of the test material or skin marker pen, or latex; or any known sensitivities/allergies, including but not limited to cosmetic/toiletry products and topically applied skin treatment products/drugs.
- Participant with a history of an acute or chronic dermatologic, medical and/or physical condition that would, in the opinion of the investigator, confound study outcomes or increase the risk associated with participation. (Note: dry skin is not an exclusion per se; however, a participant with a level of dryness on the skin of the volar forearms that would, in the opinion of the investigator, confound study outcomes or increase the risk associated with participation should be excluded.
- Participant with a history of skin cancer, or currently undergoing treatment for active cancer of any kind.
- Participant with diabetes.
- Participant with a planned medical treatme
Data sourced from ClinicalTrials.gov (NCT05109117). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.